Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol 400 + propylene glycol is a combination of two demulcents used primarily in over-the-counter ophthalmic lubricant formulations for the management of dry eye disease (DED). Polyethylene glycol 400 (PEG 400) and propylene glycol (PG) function as humectants and lubricants that supplement the natural tear film, reducing ocular surface friction and preventing desiccation of the corneal and conjunctival epithelium. In advanced formulations such as Systane Ultra, these active ingredients are often paired with hydroxypropyl-guar (HP-guar), which forms a pH-dependent viscoelastic gel matrix upon contact with the ocular surface, thereby extending the residence time of the lubricants and promoting epithelial healing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol 400 + propylene glycol.